Share this article
Share this article
PISCATAWAY, N.J., Jan. 13, 2021 /PRNewswire/ GenScript USA Inc., the world s leading research reagent provider, announced today that it has submitted an application to the U.S. Food and Drug Administration s Center for Biologics Evaluation and Research (CBER) for use of the cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in convalescent plasma screening. The kit, which has been authorized by the FDA for emergency use in clinical diagnostics laboratories, is the first commercially available product to specifically detect COVID-19 neutralizing antibodies without the use of live virus. Neutralizing antibodies block the ability of the virus to infect a cell and are widely recognized biomarkers of immunity.
Shapa Health Granted Second Patent Boosting Its Innovations in Health Management and Prevention Through a Virtual Care Model That Delivers Engagement and Sustainable Behavior Change
News provided by
Share this article
Share this article
CUPERTINO, Calif., Jan. 13, 2021 /PRNewswire/ Shapa, a leading Silicon Valley-based health IT technology company, announced the U.S. Patent and Trademark Office has granted the company its second patent (U.S. Patent # 10,885,807) in Q1 of 2021. This second patent increases Shapa s footprint within the health management space, bringing its innovative approach to cardiovascular health and blood pressure. The Shapa Health IP Portfolio, developed by co-founders Nati Lavi, Lara Felton and renowned behavioral economist Dan Ariely, continues to build on the focus of indirect feedback models for prevention, management and wellness to optimize virtual care and chronic disease management.
Share this article
Share this article
BETHESDA, Md., Jan. 13, 2021 /PRNewswire/ OrthoBethesda, a premier provider of orthopedic services in the greater Washington, DC region, today announced the appointment of Emil Engels, MD to the newly-created position of Chief Executive Officer. Dr. Engels will oversee all operations of OrthoBethesda s orthopedic centers in Bethesda and Arlington.
Dr. Engels joins OrthoBethesda with over 20 years experience in all facets of leading teams of clinical and business professionals while focusing on quality outcomes, labor efficiencies, supply chain management, volume growth drivers, and revenue cycle optimization. Prior to joining OrthoBethesda, Dr. Engels served with Mednax, Inc., a national health solutions partner, most recently as President, Northeast Market where he managed 12 practices with 800 providers across four states. Prior to that, he was a Division Medical Officer with Mednax, Inc. He has worked as a consultant in the health
HealthTronics Names Bill Linder New Chief Executive Officer
News provided by
Share this article
Share this article
AUSTIN, Texas, Jan. 13, 2021 /PRNewswire/ HealthTronics, an Austin-based provider of integrated, mobilized medical technologies and services, has named Bill Linder its new Chief Executive Officer.
Linder was formerly President of Development for Surgical Care Affiliates (SCA), a leader in outpatient surgical care with more than 230 ambulatory surgery centers across the U.S. At SCA, he held several senior operational and business development roles within executive leadership. In 2017 and 2016, he was named a Rising Star in Healthcare by
Becker s Hospital Review and
Becker s ASC Review. Prior to joining SCA, Linder held sales leadership roles with Harden Healthcare and Apria Healthcare.
ICJR Wins Appeal Against Former Management Company
Trial Court Ordered to Set a Monetary Award for Breach of Fiduciary Duty
News provided by
Share this article
Share this article
TAMPA, Fla., Jan. 13, 2021 /PRNewswire/ The International Congress for Joint Reconstruction (ICJR) is pleased to announce that an appellate court ruling in California will allow ICJR to receive monetary restitution from its former management company, Center for Healthcare Education and Research, Inc. (CHE), and the president of CHE, Mark Sacaris, for undisclosed profits obtained while the two were in a fiduciary relationship with ICJR.
In its lawsuit against CHE and Mr. Sacaris, ICJR alleged that they had secretly profited from their relationship with ICJR through undisclosed charges for management services, calculated at more than $1.4 million. The claim was based on the billing practices of CHE and Mr. Sacaris, which ICJR learned of in 2016. The trial court found that ICJR had entrusted managemen